Literature DB >> 18313027

Human RFT1 deficiency leads to a disorder of N-linked glycosylation.

Micha A Haeuptle1, François M Pujol, Christine Neupert, Bryan Winchester, Alexander J Kastaniotis, Markus Aebi, Thierry Hennet.   

Abstract

N-linked glycosylation is an essential posttranslational modification of proteins in eukaryotes. The substrate of N-linked glycosylation, dolichol pyrophosphate (DolPP)-GlcNAc(2)Man(9)Glc(3), is assembled through a complex series of ordered reactions requiring the translocation of the intermediate DolPP-GlcNAc(2)Man(5) structure across the endoplasmic-reticulum membrane. A young patient diagnosed with a congenital disorder of glycosylation characterized by an intracellular accumulation of DolPP-GlcNAc(2)Man(5) was found to carry a homozygous point mutation in the RFT1 gene. The c.199C-->T mutation introduced the amino acid substitution p.R67C. The human RFT1 protein shares 22% identity with its yeast ortholog, which is involved in the translocation of DolPP-GlcNAc(2)Man(5) from the cytosolic into the lumenal side of the endoplasmic reticulum. Despite the low sequence similarity between the yeast and the human RFT1 proteins, we demonstrated both their functional orthology and the pathologic effect of the human p.R67C mutation by complementation assay in Deltarft1 yeast cells. The causality of the RFT1 p.R67C mutation was further established by restoration of normal glycosylation profiles in patient-derived fibroblasts after lentiviral expression of a normal RFT1 cDNA. The definition of the RFT1 defect establishes the functional conservation of the DolPP-GlcNAc(2)Man(5) translocation process in eukaryotes. RFT1 deficiency in both yeast and human cells leads to the accumulation of incomplete DolPP-GlcNAc(2)Man(5) and to a profound glycosylation disorder in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18313027      PMCID: PMC2427296          DOI: 10.1016/j.ajhg.2007.12.021

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  30 in total

1.  Regulation of lutropin circulatory half-life by the mannose/N-acetylgalactosamine-4-SO4 receptor is critical for implantation in vivo.

Authors:  Yiling Mi; Steven D Shapiro; Jacques U Baenziger
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

2.  Translocation of lipid-linked oligosaccharides across the ER membrane requires Rft1 protein.

Authors:  Jonne Helenius; Davis T W Ng; Cristina L Marolda; Peter Walter; Miguel A Valvano; Markus Aebi
Journal:  Nature       Date:  2002-01-24       Impact factor: 49.962

3.  Deficiency of dolichol-phosphate-mannose synthase-1 causes congenital disorder of glycosylation type Ie.

Authors:  T Imbach; B Schenk; E Schollen; P Burda; A Stutz; S Grunewald; N M Bailie; M D King; J Jaeken; G Matthijs; E G Berger; M Aebi; T Hennet
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

4.  Dolichol phosphate mannose synthase (DPM1) mutations define congenital disorder of glycosylation Ie (CDG-Ie)

Authors:  S Kim; V Westphal; G Srikrishna; D P Mehta; S Peterson; J Filiano; P S Karnes; M C Patterson; H H Freeze
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

Review 5.  Congenital disorders of glycosylation: genetic model systems lead the way.

Authors:  M Aebi; T Hennet
Journal:  Trends Cell Biol       Date:  2001-03       Impact factor: 20.808

6.  Carbohydrate deficient glycoprotein syndrome type IV: deficiency of dolichyl-P-Man:Man(5)GlcNAc(2)-PP-dolichyl mannosyltransferase.

Authors:  C Körner; R Knauer; U Stephani; T Marquardt; L Lehle; K von Figura
Journal:  EMBO J       Date:  1999-12-01       Impact factor: 11.598

7.  A mutation in the human MPDU1 gene causes congenital disorder of glycosylation type If (CDG-If).

Authors:  C Kranz; J Denecke; M A Lehrman; S Ray; P Kienz; G Kreissel; D Sagi; J Peter-Katalinic; H H Freeze; T Schmid; S Jackowski-Dohrmann; E Harms; T Marquardt
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

8.  MPDU1 mutations underlie a novel human congenital disorder of glycosylation, designated type If.

Authors:  B Schenk; T Imbach; C G Frank; C E Grubenmann; G V Raymond; H Hurvitz; I Korn-Lubetzki; S Revel-Vik; A Raas-Rotschild; A S Luder; J Jaeken; E G Berger; G Matthijs; T Hennet; M Aebi
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

9.  Carbohydrate-deficient glycoprotein syndromes become congenital disorders of glycosylation: an updated nomenclature for CDG. First International Workshop on CDGS.

Authors:  M Aebi; A Helenius; B Schenk; R Barone; A Fiumara; E G Berger; T Hennet; T Imbach; A Stutz; C Bjursell; A Uller; J G Wahlström; P Briones; E Cardo; P Clayton; B Winchester; V Cormier-Dalre; P de Lonlay; M Cuer; T Dupré; N Seta; T de Koning; L Dorland; F de Loos; L Kupers
Journal:  Glycoconj J       Date:  1999-11       Impact factor: 2.916

10.  Requirement of the Lec35 gene for all known classes of monosaccharide-P-dolichol-dependent glycosyltransferase reactions in mammals.

Authors:  M Anand; J S Rush; S Ray; M A Doucey; J Weik; F E Ware; J Hofsteenge; C J Waechter; M A Lehrman
Journal:  Mol Biol Cell       Date:  2001-02       Impact factor: 4.138

View more
  24 in total

Review 1.  Protein secretion and the endoplasmic reticulum.

Authors:  Adam M Benham
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-08-01       Impact factor: 10.005

2.  Improvement of dolichol-linked oligosaccharide biosynthesis by the squalene synthase inhibitor zaragozic acid.

Authors:  Micha A Haeuptle; Michael Welti; Heinz Troxler; Andreas J Hülsmeier; Timo Imbach; Thierry Hennet
Journal:  J Biol Chem       Date:  2010-12-23       Impact factor: 5.157

Review 3.  Congenital disorders of glycosylation (CDG): it's (nearly) all in it!

Authors:  Jaak Jaeken
Journal:  J Inherit Metab Dis       Date:  2011-03-08       Impact factor: 4.982

4.  RFT1 Protein Affects Glycosylphosphatidylinositol (GPI) Anchor Glycosylation.

Authors:  Petra Gottier; Amaia Gonzalez-Salgado; Anant K Menon; Yuk-Chien Liu; Alvaro Acosta-Serrano; Peter Bütikofer
Journal:  J Biol Chem       Date:  2016-12-07       Impact factor: 5.157

5.  RFT1-CDG: Absence of Epilepsy and Deafness in Two Patients with Novel Pathogenic Variants.

Authors:  D Quelhas; J Jaeken; A Fortuna; L Azevedo; A Bandeira; G Matthijs; E Martins
Journal:  JIMD Rep       Date:  2018-06-20

6.  Core glycosylation of collagen is initiated by two beta(1-O)galactosyltransferases.

Authors:  Belinda Schegg; Andreas J Hülsmeier; Christoph Rutschmann; Charlotte Maag; Thierry Hennet
Journal:  Mol Cell Biol       Date:  2008-12-15       Impact factor: 4.272

7.  Suppression of Rft1 expression does not impair the transbilayer movement of Man5GlcNAc2-P-P-dolichol in sealed microsomes from yeast.

Authors:  Jeffrey S Rush; Ningguo Gao; Mark A Lehrman; Sergey Matveev; Charles J Waechter
Journal:  J Biol Chem       Date:  2009-06-03       Impact factor: 5.157

8.  RFT1 deficiency in three novel CDG patients.

Authors:  Wendy Vleugels; Micha A Haeuptle; Bobby G Ng; Jean-Claude Michalski; Roberta Battini; Carlo Dionisi-Vici; Mark D Ludman; Jaak Jaeken; François Foulquier; Hudson H Freeze; Gert Matthijs; Thierry Hennet
Journal:  Hum Mutat       Date:  2009-10       Impact factor: 4.878

9.  Deficiency of Dol-P-Man synthase subunit DPM3 bridges the congenital disorders of glycosylation with the dystroglycanopathies.

Authors:  Dirk J Lefeber; Johannes Schönberger; Eva Morava; Mailys Guillard; Karin M Huyben; Kiek Verrijp; Olga Grafakou; Athanasios Evangeliou; Frank W Preijers; Panagiota Manta; Jef Yildiz; Stephanie Grünewald; Martha Spilioti; Christa van den Elzen; Dominique Klein; Daniel Hess; Hisashi Ashida; Jan Hofsteenge; Yusuke Maeda; Lambert van den Heuvel; Martin Lammens; Ludwig Lehle; Ron A Wevers
Journal:  Am J Hum Genet       Date:  2009-07-02       Impact factor: 11.025

10.  Comprehensive description of the phenotype of the first case of congenital disorder of glycosylation due to RFT1 deficiency (CDG In).

Authors:  P T Clayton; S Grunewald
Journal:  J Inherit Metab Dis       Date:  2009-03-11       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.